Advancements in Breast Cancer Research Unveiled at SABCS 2024
• The PATINA trial suggests palbociclib with anti-HER2 and endocrine therapy may become a new standard for HR+, HER2+ metastatic breast cancer.
• COMET trial indicates active monitoring is comparable to surgery for low-risk DCIS, offering a potential alternative management option.
• OlympiA trial's long-term results reinforce olaparib's role in preventing recurrence and highlight the importance of BRCA testing for early-stage breast cancer.
Tamoxifen Reduces Long-Term Recurrence Risk in Good-Risk DCIS Without Radiation
• Adjuvant tamoxifen significantly reduces the 15-year risk of ipsilateral breast cancer recurrence in patients with good-risk DCIS who forgo radiation therapy.
• Tamoxifen notably decreases the risk of invasive ipsilateral breast cancer recurrence but does not significantly impact ipsilateral DCIS or contralateral breast cancer.
• The findings support tamoxifen as a reasonable option for good-risk DCIS patients post-surgery, aiding in informed decisions between endocrine and radiation therapies.
• The study underscores the importance of evaluating endocrine therapy's impact in patients with good-risk DCIS who do not receive radiation therapy.
© Copyright 2025. All Rights Reserved by MedPath